Specialty Pharma Journal Specialty, Precision & Technology
SAN FRANCISCO & BALLERUP, Denmark–(BUSINESS WIRE)–Danish dermatology specialists LEO Pharma and California rare disease pioneers PellePharm today announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such …
Tag Archives: Leo Pharma
November, 2018
September, 2018
-
19 September
LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics
BALLERUP, Denmark & MARTINSRIED/MUNICH, Germany–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for …
July, 2016
-
1 July
AstraZeneca Licenses Two Dermatology Drugs to Leo Pharma
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the Company to further simplify and sharpen …
November, 2015
-
11 November
Leo Pharma to Acquire Astellas’ Global Dermatology Portfolio
LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the …